This CME/CNE program will provide a comprehensive update of best practices for treating and managing patients with acute lymphoblastic leukemia (ALL). The expert faculty will outline molecular mutations and patient prognosis, including the t-acute lymphoblastic leukemia and the b-acute lymphoblastic leukemia subtypes. Current clinical trial data will be analyzed, particularly recent breakthroughs in the care of adults with ALL. The role of chimeric antigen receptor (CAR) T cell therapy in modern day care will also be reviewed. The faculty will highlight best practices for managing adverse events and administering optimal patient education utilizing the interprofessional team to improve quality of life of patients. Upon completing this interactive educational program, learner’s will be better equipped to confidently care for patients with acute lymphoblastic leukemia.
Oncologists/hematologists, primary care physicians, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with ALL
1. Identify the molecular mutations in acute lymphoblastic leukemia and their impact on patient prognosis
2. Analyze the most recent data for current and emerging therapeutics for the treatment of ALL
3. Collaborate in developing individualized treatment strategies to improve outcomes in patients with ALL
Eytan M. Stein, MD (Course Chair)
Memorial Sloan Kettering Cancer Center
New York, NY
Coleen P. Ranaghan, NP, MSN
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
|Faculty||Relationship Identified With:|
|Eytan M. Stein, MD (Course Chair)||Consultant/Advisor: Astellas Pharma US, Inc.; Agios Pharmaceuticals; Axon Therapeutics; Celgene Corporation; Daiichi Sankyo Company, Limited; Genentech, Inc.; Novartis Pharmaceuticals Corporation|
|Jae Park, MD||Consultant/Advisor: Amgen Inc.; AstraZeneca; GlaxoSmithKline plc.; Incyte Corporation; Kite Pharmaceuticals; Novartis Pharmaceuticals Corporation; Takeda Pharmaceutical Company Limited|
|Coleen P. Ranaghan, NP, MSN||Nothing to disclose|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hour). AcademicCME’s ANCC provider number is P0491.
This activity has been supported by an independent educational grant from Amgen Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
8. 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].